Form 4: KalVista Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Brian JG Pereira, a director of KalVista Pharmaceuticals, acquired stock options for 10,000 shares at an exercise price of $11.54 on October 3, 2024.
Summary
- On October 3, 2024, Brian JG Pereira, a director at KalVista Pharmaceuticals, acquired stock options for 10,000 shares.
- The exercise price for these options is $11.54.
- The options vest monthly over a 12-month period, starting November 3, 2024.
- The options expire on October 2, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a routine filing indicating a director's acquisition of stock options. It doesn't inherently suggest positive or negative implications for the company's performance.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it could be interpreted as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of the stock option transaction. |
| 11/03/2024 | First vesting date of the stock options (1/12th of the total shares). |
| 10/02/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.